<DOC>
	<DOCNO>NCT00107510</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , docetaxel carboplatin , work different way stop growth tumor cell , either kill cell stop divide . Colony-stimulating factor , pegfilgrastim , may increase number immune cell find bone marrow peripheral blood may help immune system recover side effect chemotherapy . Giving docetaxel carboplatin together pegfilgrastim surgery may shrink tumor remove . PURPOSE : This phase II trial study well give docetaxel carboplatin together pegfilgrastim work treat patient undergo surgery stage II stage III breast cancer .</brief_summary>
	<brief_title>Docetaxel , Carboplatin , Pegfilgrastim Treating Patients Who Are Undergoing Surgery Stage II Stage III Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine pathological complete response rate patient stage II III breast cancer treat neoadjuvant docetaxel , carboplatin , pegfilgrastim . Secondary - Determine toxicity profile regimen patient . - Determine rate breast-conserving surgery patient treat regimen . - Determine clinical response rate patient treat regimen . - Determine feasibility drug administration , term percent plan dose actually administer per course , patient treat regimen . - Determine proportion patient negative pathologic lymph node status treatment regimen . - Determine proportion patient residual ductal carcinoma situ treatment regimen . OUTLINE : This multicenter study . Patients receive docetaxel IV 1 hour carboplatin IV 30 minute day 1 . Patients also receive pegfilgrastim subcutaneously day 2 . Treatment repeat every 14 day 4 course absence disease progression unacceptable toxicity . No 6 week completion chemotherapy , patient undergo definitive surgery . After completion study therapy , patient follow every 6 month disease progression annually 5 year . Patients complete 4 course chemotherapy undergo surgery follow every 6 month 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis breast cancer Clinical stage II III disease ( include T24 , N03 ) No clinical radiological evidence distant metastasis Isolated supraclavicular lymph node involvement allow PATIENT CHARACTERISTICS : Age 18 Sex Male female Menopausal status Not specify Performance status ECOG 01 Life expectancy At least 3 month Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Hepatic Bilirubin normal Meets 1 follow criterion : AST ALT ≤ 5 time upper limit normal ( ULN ) AND alkaline phosphatase normal AST ALT ≤ 1.5 time ULN AND alkaline phosphatase ≤ 2.5 time ULN AST ALT normal AND alkaline phosphatase ≤ 5 time ULN Renal Creatinine clearance ≥ 30 mL/min Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception 30 day study treatment No active unresolved infection No history severe hypersensitivity reaction docetaxel , carboplatin , drug formulate polysorbate 80 No know hypersensitivity E. coliderived protein , filgrastim ( GCSF ) , pegfilgrastim No peripheral neuropathy ≥ grade 2 No invasive malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Surgery No prior surgical resection invasive breast cancer Other No prior therapy invasive breast cancer</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>male breast cancer</keyword>
</DOC>